A Global Executive, Transforming and Growing Profitable Revenue Through Innovation and Strategic Planning, At Speed And Scale

Mark Kerschner is a business leader, advisor and investor who focuses on serving early stage to mid-size companies. Mark specializes in helping companies develop and achieve their potential by assisting them in factually assessing their current condition, reviewing their operations, creating clear actionable goals and developing innovative roadmaps needed to achieve their vision. Using his extensive financial knowledge, Mark also assists companies in translating their roadmaps into comprehensive financial plans and critical KPIs. Mark has most recently been a Board Member, CFO and investor in Seneca Therapeutics, a biotechnology company. As a member of a four-person Leadership Team, he co-lead and helped take the company from therapy thesis into Phase I/II clinical trials, which are expected to be completed in 2027. Mark has been an active early-stage company investor since 2017, serving on companies’ Boards and Advisory Committees. Prior to 2017, Mark held the positions of CFO, Treasurer, CAO, General Auditor and Public Accountant in organizations such as CDI Corp., BASF Corp., ITT-Hartford Insurance Group and PWC. His work experience includes the insurance, chemicals, engineering, defense/space and life sciences industries, as well as eight years of on-the-ground international assignments. Mark’s extensive financial and business knowledge, participation in regulated and unregulated industries and his extensive multi-national experiences allow him to provide creative insights and perspectives to organizations. He understands the business opportunities and challenges companies face, as well as the pressures they confront from market participants and active shareholders.

Board Experience

  • Seneca Therapeutics, Inc.
  • Academy of Vocal Arts
  • Pennsylvania Horticultural Society

Professional Accolades

  • CPA
  • Treasury Risk Magazine – Alexander Hamilton Award